Results 41 to 50 of about 6,414,902 (294)

Minimal Residual Disease in Hematological Malignancies [PDF]

Acta Haematologica, 2004
Accessible online at: www.karger.com/aha Do you prefer quality to quantity? This question has been asked for many years. It is well known that mathematics is the science of pure quantity but what about medicine? For many years, counting cells and identifying them by microscopic inspection have determined the number of normal or abnormal cells in ...
Pia, Raanani, Andreas, Hochhaus
openaire   +2 more sources

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Kottaridis, P.D., Gale, R.E., Bowen, D.T., Langabeer, S.E., Frew, M.E., Linch, D.C.   +5 more
core  

Detection of minimal residual disease in acute lymphoblastic leukemia [PDF]

, 2010
Deep insight on Detection of minimal residual disease in acute lymphoblastic ...
D Campana, Campana, D
core   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan, Michael Abele, Calogero Virgone, Michaela Kuhlen, Ricardo Lopez‐Almarez, Tal Ben‐Ami, Ewa Bien, Maja Cesen, Malgorzata A. Krawczyk, Andrea Ferrari, Gianni Bisogno, Yves Reguerre, Dominik T. Schneider, Louise Galmiche, Jorg Fuchs, Sarah Braungart, Bilgehan Yalcin, Ines B. Brecht, Daniel Orbach   +18 more
wiley   +1 more source

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

Haematologica, 2016
Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method for minimal residual disease analysis is real-time quantitative ...
Morgane Cheminant, Coralie Derrieux, Aurore Touzart, Stéphanie Schmit, Adrien Grenier, Amélie Trinquand, Marie-Hélène Delfau-Larue, Ludovic Lhermitte, Catherine Thieblemont, Vincent Ribrag, Stéphane Cheze, Laurence Sanhes, Fabrice Jardin, François Lefrère, Richard Delarue, Eva Hoster, Martin Dreyling, Vahid Asnafi, Olivier Hermine, Elizabeth Macintyre   +19 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Introduction: Minimal residual disease is an important independent prognostic factor that can identify poor responders among patients with acute lymphoblastic leukemia.
Francisco Danilo Ferreira Paula, Silvana Maria Elói-Santos, Sandra Guerra Xavier, Mônica Aparecida Ganazza, Patricia Yoshioka Jotta, José Andrés Yunes, Marcos Borato Viana, Juliana Godoy Assumpção   +7 more
doaj   +1 more source

Safety and Effectiveness of a High‐Dose, Tailored Tissue Plasminogen Activator Therapy Protocol: A Joint Pediatric Hematology and Cardiac ICU Quality Improvement Initiative Analysis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric thromboembolism is increasingly encountered in critical care. Systemic thrombolysis with tissue plasminogen activator (tPA) facilitates vessel or valve patency, yet pediatric‐specific protocols remain undefined, and safety concerns persist. Objective To evaluate the efficacy and safety of a tailored, prolonged systemic tPA
Eran Shostak, Oded Gilad, Yael Feinstein, Sigal Nakav, Ofer Schiller, Joanne Yacobovich   +5 more
wiley   +1 more source

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute
Maura Rosane Valério Ikoma, Miriam Perlingeiro Beltrame, Silvia Inês Alejandra Cordoba Pires Ferreira, Elizabeth Xisto Souto, Mariester Malvezzi, Mihoko Yamamoto   +5 more
doaj   +1 more source